These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 1700812

  • 1. Effect of normal MSAFP screening on maternal age for genetic amniocentesis.
    Ganiats TG, Berry CC, Fullerton JT.
    J Clin Epidemiol; 1990; 43(11):1143-8. PubMed ID: 1700812
    [Abstract] [Full Text] [Related]

  • 2. Maternal serum screening in Ontario using the triple marker test.
    Summers AM, Farrell SA, Huang T, Meier C, Wyatt PR.
    J Med Screen; 2003; 10(3):107-11. PubMed ID: 14561260
    [Abstract] [Full Text] [Related]

  • 3. Maternal serum screening for Down's syndrome, open neural tube defects and trisomy 18.
    Akbas SH, Ozben T, Alper O, Ugur A, Yücel G, Lüleci G.
    Clin Chem Lab Med; 2001 Jun; 39(6):487-90. PubMed ID: 11506458
    [Abstract] [Full Text] [Related]

  • 4. Screening for Down's syndrome in older women based on maternal serum alpha-fetoprotein levels and age: preliminary results.
    Zeitune M, Ben-Tovim T, Fejgin M, Amiel A, Beyth Y.
    Prenat Diagn; 1991 Jun; 11(6):393-8. PubMed ID: 1717971
    [Abstract] [Full Text] [Related]

  • 5. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol.
    Cheng EY, Luthy DA, Zebelman AM, Williams MA, Lieppman RE, Hickok DE.
    Obstet Gynecol; 1993 Jan; 81(1):72-7. PubMed ID: 7677967
    [Abstract] [Full Text] [Related]

  • 6. Screening for Down's syndrome and neural tube defect in Croatia. A regional prospective study.
    Brajenović-Milić B, Tislarić D, Bacić J, Paravić J, Slivar AE, Kapovic M, Kosec V, Ristic S, Rajhvajn B.
    Fetal Diagn Ther; 1998 Jan; 13(6):367-71. PubMed ID: 9933821
    [Abstract] [Full Text] [Related]

  • 7. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
    McDuffie RS, Haverkamp AD, Stark CF, Haverkamp C, Barth CK.
    J Matern Fetal Med; 1996 Jan; 5(2):70-3. PubMed ID: 8796771
    [Abstract] [Full Text] [Related]

  • 8. Screening for fetal Down's syndrome in pregnancy by measuring maternal serum alpha-fetoprotein levels.
    DiMaio MS, Baumgarten A, Greenstein RM, Saal HM, Mahoney MJ.
    N Engl J Med; 1987 Aug 06; 317(6):342-6. PubMed ID: 2439909
    [Abstract] [Full Text] [Related]

  • 9. The impact of MSAFP screening on genetic services, 1984-1986.
    Greenberg F.
    Am J Med Genet; 1988 Sep 06; 31(1):223-30. PubMed ID: 2464932
    [Abstract] [Full Text] [Related]

  • 10. Cost-justification analysis of prenatal maternal serum alpha-feto protein screening.
    Taplin SH, Thompson RS, Conrad DA.
    Med Care; 1988 Dec 06; 26(12):1185-202. PubMed ID: 2462141
    [Abstract] [Full Text] [Related]

  • 11. Prenatal biochemical screening for Down's syndrome and neural tube defects.
    Wald NJ, Kennard A.
    Curr Opin Obstet Gynecol; 1992 Apr 06; 4(2):302-7. PubMed ID: 1373963
    [Abstract] [Full Text] [Related]

  • 12. Adverse perinatal outcome in patients screen-positive for neural tube defects and fetal Down syndrome.
    Gross SJ, Phillips OP, Shulman LP, Bright NL, Dungan JS, Simpson JL, Elias S.
    Prenat Diagn; 1994 Jul 06; 14(7):609-13. PubMed ID: 7526367
    [Abstract] [Full Text] [Related]

  • 13. Alpha-fetoprotein in obstetrics. Experience of a prenatal diagnosis center.
    Cariati E, Brizzi L, Periti E.
    J Nucl Med Allied Sci; 1989 Jul 06; 33(3 Suppl):72-6. PubMed ID: 2480428
    [Abstract] [Full Text] [Related]

  • 14. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening.
    Haddow JE, Palomaki GE, Knight GJ, Cunningham GC, Lustig LS, Boyd PA.
    N Engl J Med; 1994 Apr 21; 330(16):1114-8. PubMed ID: 7510852
    [Abstract] [Full Text] [Related]

  • 15. Second trimester prenatal screening for Down's syndrome using alpha-fetoprotein and free beta hCG: a seven year review.
    Spencer K.
    Br J Obstet Gynaecol; 1999 Dec 21; 106(12):1287-93. PubMed ID: 10609723
    [Abstract] [Full Text] [Related]

  • 16. Results and benefits of a maternal serum alpha-fetoprotein screening program.
    Milunsky A, Alpert E.
    JAMA; 1984 Sep 21; 252(11):1438-42. PubMed ID: 6206249
    [Abstract] [Full Text] [Related]

  • 17. [Maternal serum alpha-fetoprotein as a screening test for fetal Down syndrome].
    Bessho T, Kanazawa R, Shiotani T, Mitsuo M, Koyama K.
    Nihon Sanka Fujinka Gakkai Zasshi; 1995 Mar 21; 47(3):237-43. PubMed ID: 7535328
    [Abstract] [Full Text] [Related]

  • 18. Is maternal serum triple screening a better predictor of Down syndrome in female than in male fetuses?
    Ghidini A, Spong CY, Grier RE, Walker CN, Pezzullo JC.
    Prenat Diagn; 1998 Feb 21; 18(2):123-6. PubMed ID: 9516012
    [Abstract] [Full Text] [Related]

  • 19. Abnormal maternal serum alpha fetoprotein and pregnancy outcome.
    Zarzour SJ, Gabert HA, Diket AL, St Amant M, Miller JM.
    J Matern Fetal Med; 1998 Feb 21; 7(6):304-7. PubMed ID: 9848697
    [Abstract] [Full Text] [Related]

  • 20. First-trimester maternal serum alpha-fetoprotein and human chorionic gonadotropin screening for chromosome defects.
    Nebiolo L, Ozturk M, Brambati B, Miller S, Wands J, Milunsky A.
    Prenat Diagn; 1990 Sep 21; 10(9):575-81. PubMed ID: 1702539
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.